BCG Vaccination Policy and Protection Against COVID-19
- PDF / 152,579 Bytes
- 1 Pages / 595.276 x 790.866 pts Page_size
- 42 Downloads / 172 Views
SCIENTIFIC LETTER
BCG Vaccination Policy and Protection Against COVID-19 Jitendra Meena 1 & Arushi Yadav 2 & Jogender Kumar 3 Received: 18 May 2020 / Accepted: 28 May 2020 # Dr. K C Chaudhuri Foundation 2020
To the Editor: Wide disparity in disease burden and mortality in COVID-19 among countries is intriguing. BCG vaccine is thought to be one of the factors attributing to this discrepancy. To explore this hypothesis, we assessed the correlation of COVID-19 burden at three different time points (14 April, 29 April, and 13 May 2020) with year-wise BCG coverage among the countries with universal BCG vaccination policy over past four decades (1980–2018). Relevant data were extracted and analyzed using SPSS [1, 2]. Out of 170 countries for which data on BCG vaccination and COVID-19 was available, we excluded 28 countries ( 65 y, cardiovascular disease death rate, diabetes, GDP per capita, beds per thousand population, and the number of tests done per million population) and didn’t find any consistent and significant relationship between BCG vaccination rates and COVID-19 burden. These results suggest against any meaningful relationship between country’s BCG vaccination coverage and COVID-19 burden.
Preprint studies have reported a negative association between BCG and COVID-19 [3]. However, these associations are spurious as they chose BCG vaccination as a dichotomous variable (yes/no, counted yes even if the coverage is 5–10% and vaccination was stopped 2–3 decades back) and didn’t adjust for potential confounders [4]. The association between COVID-19 and BCG vaccine is postulated due to the non-specific effects (NSE) inherent to the vaccine. However, these NSE’s may not last beyond 5–10 y [4]. A recent study failed to show the protective effect of BCG over COVID-19 [5]. We acknowledge that these results are based on epidemiological data and have inherent biases, therefore, well-designed clinical trials are needed to test this hypothesis. Existing epidemiological evidence didn’t recommend using BCG against COVID-19 in routine clinical practice.
Compliance with Ethical Standards Conflict of Interest None.
References 1.
2. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12098-020-03371-3) contains supplementary material, which is available to authorized users.
3.
* Jogender Kumar [email protected]
4.
1
Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
5.
2
Department of Radiodiagnosis and Imaging, Government Medical College and Hospital, Chandigarh, India
3
Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India
World Health Organization. Coronavirus Disease (COVID-2019) Situation Reports. Available at: https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/situation-reports. Accessed 16 May 2020. World Health Organization. BCG Immunization Coverage Estimates By Country. Global Health Observatory Data Repository. Available at: https://apps.who.int/gho/data/view.ma
Data Loading...
